Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 132
Filter
1.
Rev. esp. patol. torac ; 34(3): 153-157, Oct. 2022. ilus
Article in Spanish | IBECS | ID: ibc-210680

ABSTRACT

Resumen abreviado: Se analizaron todas las radiografías de tórax con sospecha de afectación por COVID-19 durante la “primera ola”, aplicando el score ERVI al ingreso y correlacionando su evolución hacia fibrosis pulmonar documentada por TC, con el objetivo de identificar la relación entre ERVI grave y el desarrollo de fibrosis pulmonar.Objetivo: Analizamos todas las radiografías de tórax realizadas por el servicio de urgencias durante la primera ola de la COVID-19 con motivo de consulta “sospecha COVID-19”. Posteriormente, revisamos aplicando la escala ERVI y realizando un seguimiento de su evolución clínica y radiológica a los seis meses. Igualmente, todos aquellos pacientes positivos y que ingresaron en UCI fueron posteriormente revisados, realizando una TC de tórax de control. En el presente artículo nos centramos en intentar establecer una relación entre aquellas radiografías que presentaban un ERVI grave y el desarrollo de fibrosis pulmonar.Métodos: Identificamos un total de 653 radiografías de pacientes con clínica compatible y hallazgos sospechosos de infección por SARS-CoV-2. Del total, solo se realizaron TC de tórax a 83 pacientes, que son los que se han tenido en cuenta para este estudio, analizando la presencia de fibrosis pulmonar. Tras analizar la relación entre los valores del score ERVI y la presencia de fibrosis, en más de la mitad de los casos la fibrosis se desarrollaba en pacientes con ERVI grave al ingreso.Resultados: Existe una relación estadísticamente significativa con una p<0.005 entre la presencia de neumonía grave medida por la escala ERVI al ingreso y el posterior desarrollo de fibrosis pulmonar.Conclusiones: Consideramos sensata la recomendación de realizar seguimiento por TC a pacientes con enfermedad grave que pueda aportar datos para el diagnóstico de fibrosis pulmonar, especialmente a partir de tres semanas del inicio de los síntomas. (AU)


Short summary: All chest X-rays suspected of being affected by COVID-19 during the “first wave” were analyzed, applying the LVRI score at admission and correlating its evolution towards pulmonary fibrosis documented by CT, with the aim of identifying the relationship between severe ERVI and the development of pulmonary fibrosis.Objective: We analyzed all chest X-rays performed by the emergency department during the so-called first wave of COVID-19 with the reason for consultation "COVID-19 suspicion". Subsequently, these radiographs were reviewed, applying the ERVI scale and following their clinical and radiological evolution at six months. Similarly, all positive patients who were admitted to the ICU were subsequently reviewed and a control chest CT scan was performed. In the present article we focus on trying to establish a relationship between those radiographs showing severe ERVI and the development of pulmonary fibrosis.Methods: A total of 653 radiographs of patients with compatible symptoms and suspicious findings of SARS-CoV-2 infection have been identified. Of the total number of patients, chest CT scans were only performed in 83 patients, which are the ones taken into account for this study, analyzing the presence of pulmonary fibrosis. After analyzing the relationship between ERVI score values and the presence of fibrosis, in more than half of the cases patients with severe ERVI at admission developed pulmonary fibrosis.Results: We demonstrateda statistically significant association (p<0.005) between the presence of severe pneumonia measured by the ERVI scale on admission and the subsequent development of pulmonary fibrosis.Conclusions: We recommend CT follow-up of patients with severe disease that can provide data for the diagnosis of pulmonary fibrosis, especially if it is performed three weeks after the onset of symptoms. (AU)


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Pandemics , Coronavirus Infections/epidemiology , Severe acute respiratory syndrome-related coronavirus , Pulmonary Fibrosis , Retrospective Studies , Hospitals, University , Radiography
2.
AJNR Am J Neuroradiol ; 43(9): 1265-1270, 2022 09.
Article in English | MEDLINE | ID: mdl-35981763

ABSTRACT

BACKGROUND AND PURPOSE: CTP allows estimating ischemic core in patients with acute stroke. However, these estimations have limited accuracy compared with MR imaging. We studied the effect of applying WM- and GM-specific thresholds and analyzed the infarct growth from baseline imaging to reperfusion. MATERIALS AND METHODS: This was a single-center cohort of consecutive patients (n = 113) with witnessed strokes due to proximal carotid territory occlusions with baseline CT perfusion, complete reperfusion, and follow-up DWI. We segmented GM and WM, coregistered CTP with DWI, and compared the accuracy of the different predictions for each voxel on DWI through receiver operating characteristic analysis. We assessed the yield of different relative CBF thresholds to predict the final infarct volume and an estimated infarct growth-corrected volume (subtracting the infarct growth from baseline imaging to complete reperfusion) for a single relative CBF threshold and GM- and WM-specific thresholds. RESULTS: The fixed threshold underestimated lesions in GM and overestimated them in WM. Double GM- and WM-specific thresholds of relative CBF were superior to fixed thresholds in predicting infarcted voxels. The closest estimations of the infarct on DWI were based on a relative CBF of 25% for a single threshold, 35% for GM, and 20% for WM, and they decreased when correcting for infarct growth: 20% for a single threshold, 25% for GM, and 15% for WM. The combination of 25% for GM and 15% for WM yielded the best prediction. CONCLUSIONS: GM- and WM-specific thresholds result in different estimations of ischemic core in CTP and increase the global accuracy. More restrictive thresholds better estimate the actual extent of the infarcted tissue.


Subject(s)
Brain Ischemia , Stroke , Humans , Stroke/pathology , Magnetic Resonance Imaging , Infarction/diagnostic imaging , Cerebrovascular Circulation , Perfusion Imaging/methods , Tomography, X-Ray Computed/methods , Perfusion , Brain Ischemia/diagnostic imaging , Brain Ischemia/pathology
3.
S Afr J Sports Med ; 34(1): v34i1a12754, 2022.
Article in English | MEDLINE | ID: mdl-36815929

ABSTRACT

Background: Tendinopathy is highly prevalent in the general public and common in athletes. It makes up nearly 50% of all sport injuries. A number of treatment techniques with varying evidence of effectiveness are currently available. Intratissue percutaneous electrolysis (EPI) is one such modality, however little consensus exists for EPI's efficacy or the most effective treatment parameters. Objective: To review and appraise available evidence for Intratissue Percutaneous Electrolysis (EPI) in the treatment of tendinopathy, examining the effectiveness of EPI in conjunction with other modalities and identifying the strengths and limitations of the evidence base for EPI in order to make evidence-based recommendation for future studies of EPI. Methods: PubMed, Embase and Scopus were searched with keywords related to EPI and tendinopathy. Grey literature searches were conducted with Embase, OpenGrey, and ProQuest. Extensive citation searching was undertaken. Randomised controlled trials (RCTs), uncontrolled and observational studies of the application of EPI in patients aged 18-65 years with Magnetic Resonance Imaging (MRI) or clinical Ultrasonography (US) confirmed diagnosis of tendinopathy were eligible. Results: Eleven studies met inclusion criteria: six randomised control trials (RCTs) and five uncontrolled studies. Clinical trials of EPI as an adjunct modality with physical therapy reporting greater decreased pain and return to function than treatment with physical therapy alone. The evidence for EPI is limited and influenced by small sample sizes, varying treatment protocols, clinical heterogeneity and high risk of bias. Conclusion: It is currently not possible to conclude that EPI is an effective modality for the treatment of tendinopathy. RCTs with clearly described EPI treatment protocols, larger sample sizes and intervention reporting sufficient to support reproducibility are needed to determine the effectiveness of EPI for the treatment of tendinopathy.

4.
Med Teach ; 42(9): 1051-1057, 2020 09.
Article in English | MEDLINE | ID: mdl-32697116

ABSTRACT

BACKGROUND: Medical curricula have historically been designed in a top-down approach, usually excluding students. While Delphi panels have been used as a tool for medical education curricula design, none have been conducted in Ecuador. In addition, no such approach has ever included students both as panelists and researchers. MATERIAL AND METHODS: Four Delphi panels were developed and conducted using a participatory approach that allowed medical students to take part both as expert panelists and researchers: specifically, students developed the questionnaire and conducted a qualitative synthesis. Questionnaire responses were anonymized and dispatched online to panelists. The information was organized and collected to develop the qualitative syntheses and prepare the final statements. RESULTS: Thirty-two medical students participated between February and May 2018. A total of 32 questions were developed, corresponding to five different categories. For some questions, consensus was reached; for other questions, general statements were obtained.Discussion and conclusion: Developing the questionnaire, responding to it and analyzing the answers allowed students to raise significant concerns regarding medical education topics proposing relevant policy and curricula change. Participatory Delphi panels can be an efficient tool to obtain organized feedback, improve student class involvement, and promote research skills.


Subject(s)
Education, Medical, Undergraduate , Education, Medical , Students, Medical , Curriculum , Delphi Technique , Ecuador , Humans
5.
Environ Sci Technol ; 52(17): 9954-9963, 2018 09 04.
Article in English | MEDLINE | ID: mdl-30063828

ABSTRACT

The interaction of engineered nanoparticles with plant tissues is still not well understood. There is a lack of information about the effects of curing (postharvest treatment) and lignin content on copper uptake by sweetpotato roots exposed to copper-based nanopesticides. In this study, Beauregard-14 (lower lignin) and Covington (higher lignin) varieties were exposed to CuO nanoparticles (nCuO), bulk CuO (bCuO), and CuCl2 at 0, 25, 75, and 125 mg/L. Cured and uncured roots were submerged into copper suspensions/solutions for 30 min. Subsequently, root segments were sliced for imaging with a 2-photon microscope, while other root portions were severed into periderm, cortex, perimedulla, and medulla. They were individually digested and analyzed for Cu content by inductively coupled plasma-optical emission spectroscopy. Microscopy images showed higher fluorescence in periderm and cortex of roots exposed to nCuO, compared with bCuO. At 25 mg/L, only bCuO showed higher Cu concentration in the periderm and cortex of Beauregard-14 (2049 mg/kg and 76 mg/kg before curing; 6769 mg/kg and 354 mg/kg after curing, respectively) and in cortex of Covington (692 mg/kg before curing and 110 mg/kg after curing) compared with controls ( p ≤ 0.05). In medulla, the most internal tissue, only Beauregard-14 exposed to 125 mg bCuO/L showed significantly ( p ≤ 0.05) more Cu before curing (17 mg/kg) and after curing (28 mg/kg), compared with control. This research has shown that the 2-photon microscope can be used to determine CuO particles in nondyed plant tissues. The lack of Cu increase in perimedulla and medulla, even in roots exposed to high CuO concentrations (125 mg/L), suggests that nCuO may represent a good alternative to protect and increase the shelf life of sweetpotato roots, without exposing consumers to excess Cu.


Subject(s)
Ipomoea batatas , Metal Nanoparticles , Nanoparticles , Copper , Microscopy , Oxides , Plant Roots , Spectrum Analysis
6.
Lupus ; 27(13): 2155-2160, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30111238

ABSTRACT

OBJECTIVE: The objective was to assess the proportion of Th1, Th2 and Th17 phenotypes in senescent CD4+CD28null cells from patients with systemic lupus erythematosus (SLE) and its association with the pattern of joint involvement. METHODS: This cross-sectional study was performed in SLE patients with erosive arthritis (rhupus) or nondeforming, nonerosive arthritis. Total CD4+CD28null cells as well as the proportion of these cells expressing T-bet, GATA3 or RORγt were analyzed by color-flow cytometry. Serum osteopontin levels were measured by ELISA. RESULTS: Eighteen SLE patients (nine with rhupus and nine with nonerosive arthritis) were studied. The percentage of CD4+CD28null/CD4+ cells (17.7%, 10.3-25.0% versus 9.4%, 8.1-22.4%; P = 0.386) as well as the osteopontin levels (5800, 5,134-5995 pg/ml versus 5578, 5171-5717 pg/ml; P > 0.05) were similar in both groups. A higher percentage of CD4+CD28nullT-bet+ cells (42.8%, 33.5-53.4% versus 30.0%, 23.3-34.2%) but a lower percentage of CD4+CD28nullGATA3+ cells (3.1%, 1.7-5.6% versus 6.2%, 2.6-18.4%) was observed in patients with rhupus than in their counterparts ( P = 0.016). The frequency of CD4+CD28nullRORγt+ cells was similar between groups. CONCLUSIONS: In patients with rhupus, senescent CD4+CD28null cells are preferentially polarized to a Th1 phenotype, whereas this is partial towards Th2 in lupus patients with a nonerosive arthritis pattern.


Subject(s)
Arthritis/complications , Lupus Erythematosus, Systemic/complications , T-Lymphocytes, Helper-Inducer/cytology , Adult , Cross-Sectional Studies , Female , Flow Cytometry , Humans , Male , Mexico , Middle Aged , Phenotype
7.
Acta pediatr. esp ; 75(11/12): e210-e213, nov.-dic. 2017. ilus, tab
Article in Spanish | IBECS | ID: ibc-170226

ABSTRACT

El os supranavicular es un hueso accesorio del pie, poco frecuente, situado en la cara superior de la articulación talonavicular. Raramente sintomático, provoca dolor en el dorso del pie y se diagnostica a menudo de forma errónea como una fractura por avulsión, por lo que es importante tener un conocimiento anatómico adecuado y realizar un buen diagnóstico diferencial. Presentamos el caso de un niño de 8 años de edad, con hueso supranavicular sintomático bilateral, que acude a nuestra consulta por un dolor mecánico en la región dorsal de ambos pies, que se intensifica tras la actividad física. Es fundamental realizar una anamnesis y una exploración física completas para establecer una adecuada orientación diagnóstica. El diagnóstico final se logra mediante la realización de pruebas complementarias, principalmente la proyección lateral de una radiografía simple de ambos pies en carga. El objetivo del tratamiento conservador (ortesis plantar, fundamentalmente) es establecer la función óptima del pie durante las actividades de carga. Si éste no proporciona un alivio tras 4-6 meses de seguimiento, debería considerarse el tratamiento quirúrgico, que consiste en la escisión simple del hueso accesorio (AU)


The os supranavicular is an accessory bone of the foot with low prevalence and it is located on the dorsal aspect of the talonavicular joint. Rarely symptomatic, it causes dorsal foot pain and it is often misdiagnosed as avulsion fracture, so it is important to have a correct anatomical knowledge and to make a good differential diagnosis. We show an eight years old child with symptomatic and bilateral supranavicular accessory bone, who presents mechanical dorsal foot pain related to physical activity. It is essential to do a complete anamnesis and physical exploration so it can be established a good diagnostic orientation. The final diagnosis is obtained by complementary tests, lateral radiograph of both load feet mainly. The aim of the conservative treatment (foot orthesis mostly) is to settle an optimal function of the foot during the loading activities. If there is no relieve after 4-6 months follow up, it should be considered surgical treatment, which consists on a simple resection of the accessory bone (AU)


Subject(s)
Humans , Foot Deformities/diagnostic imaging , Pain/etiology , Tarsal Bones/abnormalities , Anatomic Variation , Fractures, Avulsion/diagnostic imaging , Diagnosis, Differential
8.
Brain Behav Immun ; 65: 43-56, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28512033

ABSTRACT

Emerging evidence suggests that there is a window of opportunity within the early developmental period, when microbiota-based interventions could play a major role in modulating the gut-brain axis and, thereby, in preventing mood disorders. This study aims at evaluating the effects and mode of action of Bifidobacterium pseudocatenulatum CECT 7765 in a murine model of chronic stress induced by maternal separation (MS). C57Bl/6J male breast-fed pups were divided into four groups, which were subjected or not to MS and supplemented with placebo or B. pseudocatenulatum CECT7765 until postnatal period (P) 21 and followed-up until P41. Behavioral tests were performed and neuroendocrine parameters were analyzed including corticosterone, cytokine/chemokine concentrations and neurotransmitters. Microbiota was also analyzed in stools by 16S rRNA gene sequencing. B. pseudocatenulatum CECT 7765 administration attenuated some aspects of the excessive MS-induced stress response of the hypothalamic-pituitary-adrenal (HPA) axis, particularly corticosterone production at baseline and in response to subsequent acute stress in adulthood. B. pseudocatenulatum CECT 7765 also down-regulated MS-induced intestinal inflammation (reducing interferon gamma [IFN-γ]) and intestinal hypercatecholaminergic activity (reducing dopamine [DA] and adrenaline [A] concentrations) at P21. These effects have a long-term impact on the central nervous system (CNS) of adult mice since MS mice fed B. pseudocatenulatum CECT 7765 showed lower anxiety levels than placebo-fed MS mice, as well as normal neurotransmitter levels in the hypothalamus. The anti-inflammatory effect of B. pseudocatenulatum CECT 7765 seemed to be related to an improvement in glucocorticoid sensitivity in mesenteric lymph node immunocompetent cells at P21. The administration of B. pseudocatenulatum CECT 7765 to MS animals also reversed intestinal dysbiosis affecting the proportions of ten Operational Taxonomic Units (OTUs) at P21, which could partly explain the restoration of immune, neuroendocrine and behavioral alterations caused by stress in early and later life. In summary, we show that B. pseudocatenulatum CECT 7765 is able to beneficially modulate the consequences of chronic stress on the HPA response produced by MS during infancy with long-lasting effects in adulthood, via modulation of the intestinal neurotransmitter and cytokine network with short and long-term consequences in brain biochemistry and behavior.


Subject(s)
Bifidobacterium/physiology , Stress, Physiological/drug effects , Stress, Physiological/physiology , Animals , Bifidobacterium/metabolism , Central Nervous System/microbiology , Central Nervous System/physiology , Cytokines/blood , Diet, High-Fat , Dietary Supplements , Hypothalamo-Hypophyseal System/metabolism , Inflammation/immunology , Intestines/microbiology , Male , Maternal Deprivation , Mice , Mice, Inbred C57BL , Microbiota/physiology , Neurosecretory Systems , Neurotransmitter Agents/metabolism , Obesity/immunology , Pituitary-Adrenal System/metabolism , Probiotics , RNA, Ribosomal, 16S/genetics
9.
J Investig Allergol Clin Immunol ; 26(6): 366-373, 2016.
Article in English | MEDLINE | ID: mdl-27996943

ABSTRACT

INTRODUCTION: Hymenoptera venom immunotherapy (VIT) is an effective treatment but not one devoid of risk, as both local and systemic adverse reactions may occur, especially in the initial phases. We compared the tolerance to 3 VIT buildup protocols and analyzed risk factors associated with adverse reactions during this phase. MATERIALS AND METHODS: We enrolled 165 patients divided into 3 groups based on the buildup protocol used (3, 4, and 9 weeks). The severity of systemic reactions was evaluated according to the World Allergy Organization model. Results were analyzed using exploratory descriptive statistics, and variables were compared using analysis of variance. RESULTS: Adverse reactions were recorded in 53 patients (32%) (43 local and 10 systemic). Local reactions were immediate in 27 patients (63%) and delayed in 16 (37%). The severity of the local reaction was slight/moderate in 15 patients and severe in 13. Systemic reactions were grade 1-2. No significant association was found between the treatment modality and the onset of local or systemic adverse reactions or the type of local reaction. We only found a statistically significant association between severity of the local reaction and female gender. As for the risk factors associated with systemic reactions during the buildup phase, we found no significant differences in values depending on the protocol used or the insect responsible. CONCLUSIONS: The buildup protocols compared proved to be safe and did not differ significantly from one another. In the population studied, patients undergoing the 9-week schedule presented no systemic reactions. Therefore, this protocol can be considered the safest approach.


Subject(s)
Arthropod Venoms/administration & dosage , Desensitization, Immunologic/methods , Hymenoptera/immunology , Hypersensitivity/therapy , Insect Bites and Stings/therapy , Adolescent , Adult , Aged , Animals , Arthropod Venoms/adverse effects , Arthropod Venoms/immunology , Child , Desensitization, Immunologic/adverse effects , Drug Administration Schedule , Female , Humans , Hypersensitivity/diagnosis , Hypersensitivity/immunology , Immune Tolerance , Insect Bites and Stings/diagnosis , Insect Bites and Stings/immunology , Male , Middle Aged , Prospective Studies , Severity of Illness Index , Spain , Time Factors , Treatment Outcome , Young Adult
10.
Neurología (Barc., Ed. impr.) ; 31(7): 473-481, sept. 2016. tab, graf, ilus
Article in Spanish | IBECS | ID: ibc-155608

ABSTRACT

Introducción: Existe un creciente interés en las nuevas estrategias terapéuticas para la enfermedad de Alzheimer (EA) orientadas a reducir la carga de péptido β-amiloide (Aβ) en el cerebro mediante el secuestro de Aβ en el plasma, un alto porcentaje del cual se encuentra unido a albúmina y otras proteínas plasmáticas. En esta revisión, se analizan los conceptos de interacción entre Aβ y albúmina que han conducido al desarrollo del proyecto AMBAR (Alzheimer Management By Albumin Replacement), un nuevo estudio clínico multicéntrico, aleatorizado y controlado para el tratamiento de la EA. Desarrollo: Resultados de estudios de investigación básica indican que Albutein(R) (albúmina terapéutica, Grifols) contiene niveles no cuantificables de Aβ. Asimismo demuestran la capacidad de Albutein(R) de unirse a Aβ. Por otro lado, en la EA existe un elevado estrés nitro-oxidativo asociado a los agregados fibrilares de Aβ que puede inducir la modificación de la albúmina, afectando a sus funciones biológicas. Resultados del estudio en fase II confirman que el reemplazo de la albúmina endógena con Albutein(R) 5% mediante aféresis terapéutica es factible y seguro en pacientes con EA, produciendo una movilización de Aβ, además de una mejoría cognitiva de los pacientes tratados. En el estudio AMBAR se ensayará el uso combinado de aféresis terapéutica y hemoféresis con el posible efecto potenciador de Albutein(R) con reposición de inmunoglobulina por vía intravenosa (Flebogamma ® DIF). Se evaluarán los cambios cognitivos, funcionales y conductuales en pacientes con EA leve o moderada. Conclusiones: El estudio AMBAR representa una nueva perspectiva terapéutica ante la EA


Introduction: There is a growing interest in new therapeutic strategies for the treatment of Alzheimer disease (AD) which focus on reducing the beta-amyloid peptide (Aβ) burden in the brain by sequestering plasma Aβ, a large proportion of which is bound to albumin and other proteins. This review discusses the concepts of interaction between Aβ and albumin that have given rise to AMBAR (Alzheimer's Disease Management by Albumin Replacement) project, a new multicentre, randomised, controlled clinical trial for the treatment of AD. Development: Results from preliminary research suggest that Albutein(R) (therapeutic albumin, Grifols) contains no quantifiable levels of Aβ. Studies also show that Albutein(R) has Aβ binding capacity. On the other hand, AD entails a high level of nitro-oxidative stress associated with fibrillar aggregates of Aβ that can induce albumin modification, thus affecting its biological functions. Results from the phase II study confirm that using therapeutic apheresis to replace endogenous albumin with Albutein(R) 5% is feasible and safe in patients with AD. This process resulted in mobilisation of Aβ and cognitive improvement in treated patients. The AMBAR study will test combination therapy with therapeutic apheresis and haemopheresis with the possible leverage effect of Albutein(R) with intravenous immunoglobulin replacement (Flebogamma® DIF). Cognitive, functional, and behavioural changes in patients with mild to moderate AD will be assessed. Conclusions: the AMBAR study represents a new therapeutic perspective for AD


Subject(s)
Humans , Male , Female , Alzheimer Disease/therapy , Blood Component Removal/instrumentation , Blood Component Removal/methods , Albumins/therapeutic use , Immunoglobulins/therapeutic use , Enzyme-Linked Immunosorbent Assay/instrumentation , Enzyme-Linked Immunosorbent Assay/methods , Enzyme-Linked Immunosorbent Assay
11.
Actas urol. esp ; 40(3): 164-172, abr. 2016. graf, ilus
Article in Spanish | IBECS | ID: ibc-150987

ABSTRACT

Objetivos: Recientemente, el Estudio Aleatorizado Europeo de Screening del Cáncer de Próstata consiguió una reducción de la mortalidad por cáncer de próstata mediante la determinación sérica de antígeno específico-prostático (PSA). Estos resultados no fueron reproducidos en la rama española del Estudio Aleatorizado Europeo de Screening del Cáncer de Próstata. La contaminación de PSA (determinación oportunista fuera del estudio) podría disminuir el poder de contraste del estudio si se lleva a cabo en el brazo control. Hemos calculado la tasa de contaminación de PSA a largo plazo, y su efecto en la realización de biopsia prostática y en la detección de cáncer. Material y métodos: Se aleatorizaron 4.276 varones (2.415 brazo screening, 1.861 brazo control) en la sección española del Estudio Aleatorizado Europeo de Screening del Cáncer de Próstata. No se programó la determinación de PSA en el brazo control. Se indicó biopsia prostática sextante si PSA ≥ 3 ng/ml. Toda determinación de PSA realizada fuera del estudio fue etiquetada como «contaminación de PSA». Se calcularon las tasas de contaminación de PSA, realización de biopsia y detección de cáncer. Resultados: Las medianas de edad y tiempo de seguimiento fueron de 57 y 15,1 años respectivamente. Un total de 2.511 varones se realizó al menos una determinación de PSA fuera del estudio. La contaminación de PSA a los 5, 10 y 15 años fue del 22; 47,1 y 66,3% en el brazo screening, y del 20,8; 43,2 y 58,6 en el brazo control, respectivamente (p < 0,0001). La tasa de biopsia a los 5, 10 y 15 años fue del 19,3; 22,6 y 24,1% (screening) y del 1; 3,6 y 7,1% (control), respectivamente (p < 0,0001). La detección de cáncer de próstata fue del 6,7% (screening) y del 4,3% (control, p = 0,0006). Conclusiones: Aunque la contaminación acumulada de PSA fue notable en los 2 brazos del estudio, la realización de biopsia prostática fue escasa en el brazo control. Por ello, creemos que el impacto de la contaminación de PSA sobre el poder estadístico del estudio debe ser limitado


Objectives: Recently, the European Randomized Study of Screening for Prostate Cancer achieved a reduction in prostate cancer mortality by measuring serum prostate-specific antigen (PSA) levels. These results were not reproduced in the Spanish arm of European Randomized Study of Screening for Prostate Cancer. PSA contamination (opportunistic measurements outside the study) could decrease the study's contrasting power if performed in the control arm. We have calculated the long-term rate of PSA contamination and its effect on performing prostate biopsy and detecting cancer. Material and methods: A total of 4,276 men were randomised (2,415 to the screening arm, 1,861 to the control arm) in the Spanish section of the European Randomized Study of Screening for Prostate Cancer. PSA measurements were not scheduled in the control arm. Sextant prostate biopsy was indicated if PSA levels were ≥ 3 ng/mL. All PSA readings performed outside the study were labelled as "PSA contamination". We calculated the rates of PSA contamination, biopsy implementation and cancer detection. Results: The median age and follow-up time were 57 and 15.1 years, respectively. A total of 2,511 men underwent at least one PSA reading outside the study. PSA contamination at 5, 10 and 15 years was 22.0%, 47.1% and 66.3% in the screening arm, respectively, and 20.8%, 43.2% and 58.6% in the control arm, respectively (P < .0001). The biopsy rate at 5, 10 and 15 years was 19.3%, 22.6% and 24.1% (screening), respectively, and 1.0%, 3.6% and 7.1% (control), respectively (P < .0001). The PC detection rate was 6.7% (screening) and 4.3% (control; P = .0006). Conclusions: Although the cumulative PSA contamination was pronounced in the 2 study arms, the rate of prostate biopsies was low in the control arm. We therefore believe that the effect of PSA contamination on the study's statistical power should be limited


Subject(s)
Humans , Male , Middle Aged , Aged , Prostatic Neoplasms/blood , Prostatic Neoplasms/diagnosis , Prostate-Specific Antigen/blood , Biopsy , Early Detection of Cancer , Time Factors
12.
Actas Urol Esp ; 40(3): 164-72, 2016 Apr.
Article in English, Spanish | MEDLINE | ID: mdl-26620123

ABSTRACT

OBJECTIVES: Recently, the European Randomized Study of Screening for Prostate Cancer achieved a reduction in prostate cancer mortality by measuring serum prostate-specific antigen (PSA) levels. These results were not reproduced in the Spanish arm of European Randomized Study of Screening for Prostate Cancer. PSA contamination (opportunistic measurements outside the study) could decrease the study's contrasting power if performed in the control arm. We have calculated the long-term rate of PSA contamination and its effect on performing prostate biopsy and detecting cancer. MATERIAL AND METHODS: A total of 4,276 men were randomised (2,415 to the screening arm, 1,861 to the control arm) in the Spanish section of the European Randomized Study of Screening for Prostate Cancer. PSA measurements were not scheduled in the control arm. Sextant prostate biopsy was indicated if PSA levels were ≥3 ng/mL. All PSA readings performed outside the study were labelled as "PSA contamination". We calculated the rates of PSA contamination, biopsy implementation and cancer detection. RESULTS: The median age and follow-up time were 57 and 15.1 years, respectively. A total of 2,511 men underwent at least one PSA reading outside the study. PSA contamination at 5, 10 and 15 years was 22.0%, 47.1% and 66.3% in the screening arm, respectively, and 20.8%, 43.2% and 58.6% in the control arm, respectively (P<.0001). The biopsy rate at 5, 10 and 15 years was 19.3%, 22.6% and 24.1% (screening), respectively, and 1.0%, 3.6% and 7.1% (control), respectively (P<.0001). The PC detection rate was 6.7% (screening) and 4.3% (control; P=.0006). CONCLUSIONS: Although the cumulative PSA contamination was pronounced in the 2 study arms, the rate of prostate biopsies was low in the control arm. We therefore believe that the effect of PSA contamination on the study's statistical power should be limited.


Subject(s)
Prostate-Specific Antigen/blood , Prostatic Neoplasms/blood , Prostatic Neoplasms/diagnosis , Aged , Biopsy , Early Detection of Cancer , Humans , Male , Middle Aged , Time Factors
13.
Neurologia ; 31(7): 473-81, 2016 Sep.
Article in English, Spanish | MEDLINE | ID: mdl-25023458

ABSTRACT

INTRODUCTION: There is a growing interest in new therapeutic strategies for the treatment of Alzheimer disease (AD) which focus on reducing the beta-amyloid peptide (Aß) burden in the brain by sequestering plasma Aß, a large proportion of which is bound to albumin and other proteins. This review discusses the concepts of interaction between Aß and albumin that have given rise to AMBAR (Alzheimer's Disease Management by Albumin Replacement) project, a new multicentre, randomised, controlled clinical trial for the treatment of AD. DEVELOPMENT: Results from preliminary research suggest that Albutein(®) (therapeutic albumin, Grifols) contains no quantifiable levels of Aß. Studies also show that Albutein(®) has Aß binding capacity. On the other hand, AD entails a high level of nitro-oxidative stress associated with fibrillar aggregates of Aß that can induce albumin modification, thus affecting its biological functions. Results from the phase ii study confirm that using therapeutic apheresis to replace endogenous albumin with Albutein(®) 5% is feasible and safe in patients with AD. This process resulted in mobilisation of Aß and cognitive improvement in treated patients. The AMBAR study will test combination therapy with therapeutic apheresis and haemopheresis with the possible leverage effect of Albutein(®) with intravenous immunoglobulin replacement (Flebogamma(®) DIF). Cognitive, functional, and behavioural changes in patients with mild to moderate AD will be assessed. CONCLUSIONS: the AMBAR study represents a new therapeutic perspective for AD.


Subject(s)
Albumins/isolation & purification , Albumins/therapeutic use , Alzheimer Disease/therapy , Immunoglobulins, Intravenous/therapeutic use , Plasma Exchange/methods , Plasmapheresis/methods , Aged , Aged, 80 and over , Albumins/chemistry , Amyloid beta-Peptides/metabolism , Humans , Protein Binding
14.
J. investig. allergol. clin. immunol ; 26(6): 366-373, 2016. tab
Article in English | IBECS | ID: ibc-159024

ABSTRACT

Introduction: Hymenoptera venom immunotherapy (VIT) is an effective treatment but not one devoid of risk, as both local and systemic adverse reactions may occur, especially in the initial phases. We compared the tolerance to 3 VIT buildup protocols and analyzed risk factors associated with adverse reactions during this phase. Materials and Methods: We enrolled 165 patients divided into 3 groups based on the buildup protocol used (3, 4, and 9 weeks). The severity of systemic reactions was evaluated according to the World Allergy Organization model. Results were analyzed using exploratory descriptive statistics, and variables were compared using analysis of variance. Results: Adverse reactions were recorded in 53 patients (32%) (43 local and 10 systemic). Local reactions were immediate in 27 patients (63%) and delayed in 16 (37%). The severity of the local reaction was slight/moderate in 15 patients and severe in 13. Systemic reactions were grade 1-2. No significant association was found between the treatment modality and the onset of local or systemic adverse reactions or the type of local reaction. We only found a statistically significant association between severity of the local reaction and female gender. As for the risk factors associated with systemic reactions during the buildup phase, we found no significant differences in values depending on the protocol used or the insect responsible. Conclusions: The buildup protocols compared proved to be safe and did not differ significantly from one another. In the population studied, patients undergoing the 9-week schedule presented no systemic reactions. Therefore, this protocol can be considered the safest approach (AU)


Introducción: La inmunoterapia con veneno de himenópteros (ITV) es un tratamiento eficaz, pero no está desprovisto de riesgo ya que pueden ocurrir reacciones adversas locales o sistémicas, especialmente en las etapas iniciales del tratamiento. Comparamos la tolerancia de tres protocolos de inicio de ITV y analizamos los factores de riesgo asociados con las reacciones adversas que se produjeron en esta fase. Métodos: Se incluyeron 165 pacientes divididos en tres grupos según el protocolo de iniciación utilizado (3, 4 o 9 semanas). Evaluamos la gravedad de las reacciones sistémicas de acuerdo con el modelo de la Organización Mundial de Alergia. Analizamos los resultados mediante estadística descriptiva exploratoria y comparamos variables mediante el análisis de la varianza. Resultados: Cincuenta y tres pacientes (32%) experimentaron algún tipo de reacción adversa; 43 eran locales y 10 sistémicas. Las reacciones locales fueron inmediatas en 27 pacientes (63%) y tardías en 16 (37%). La gravedad de la reacción local fue leve o moderada en 15 pacientes y grave en 13. Las reacciones sistémicas fueron de grado 1 o 2. No encontramos asociación significativa entre la modalidad de tratamiento y la aparición de reacciones adversas locales o sistémicas o el tipo de reacción local. Solo encontramos una asociación estadísticamente significativa de la gravedad de la reacción local con el sexo femenino. En cuanto a los factores de riesgo asociados con las reacciones sistémicas en la fase de inicio, no se encontraron diferencias significativas en estos valores en función del protocolo utilizado o el insecto responsable. Conclusiones: Los protocolos de inicio comparados demostraron ser seguros y no difirieron significativamente entre sí. En la población estudiada, el protocolo de 9-semanas no produjo reacciones sistémicas, por lo que se puede considerar el protocolo más seguro (AU)


Subject(s)
Humans , Male , Female , Insect Bites and Stings/immunology , Poisons/immunology , Immunotherapy/methods , Immunotherapy , Desensitization, Immunologic/methods , Risk Factors , Hymenoptera/immunology , 35170/methods , Spain/epidemiology , Prospective Studies
15.
Actas urol. esp ; 39(7): 405-413, sept. 2015. tab, graf
Article in Spanish | IBECS | ID: ibc-143728

ABSTRACT

Objetivo: En la actualidad el papel del screening del cáncer de próstata (CaP) está cuestionado. El estudio aleatorizado europeo de screening del cáncer de próstata (ERSPC) tiene como objetivo demostrar si elscreening del CaP reduce la mortalidad por esta enfermedad. Se muestran los resultados en la rama española de este estudio: mortalidad global y cáncer-específica, características de los tumores detectados, de los tratamientos primarios y de la progresión a enfermedad avanzada. Material y métodos: Se invitó a participar a 18.612 varones entre los 45 y 70 años de edad, excluyendo aquellos con una expectativa de vida inferior a 10 años. Se llevó a cabo aleatorización a brazo screening (determinación de PSA sérico) y brazo control (no pruebas diagnósticas). Se indicó biopsia prostática aleatorizada sextante dirigida por ecografía transrectal en los varones del brazo screening con PSA ≥ 3 ng/ml. Se identificaron los CaP detectados (estadio y tratamiento primarios), así como los fallecimientos producidos (fecha y causa de la muerte). Resultados: El estudio se llevó a cabo con 4.276 varones (2.415 brazo screening, 1.861 brazo control). Las medianas de edad y PSA sérico fueron de 57 años y 0,90 ng/ml respectivamente. El tiempo de seguimiento (mediana) fue de 15,8 años. Se diagnosticaron 242 CaP, 162 (6,7%) en el brazo screening y 80 (4,3%) en el control (p < 0,001). De ellos 214 (88,4%) comenzaron con estadio clínico organoconfinado (91,4% brazo screening vs 82,5% control, p = 0,024). Un total de 112 pacientes (46,3%) fue sometido a prostatectomía radical, 53 (21,9%) a radioterapia prostática, 24 (9,9%) a tratamiento hormonal y 47 (19,4%) a observación. Un total de 18 CaP evolucionaron a enfermedad avanzada (M+ o PSA > 100 ng/ml), sin diferencia entre los brazos del estudio (p = 0,938). Un total de 618 (14,5%) fallecieron a lo largo del seguimiento: 340 (14,1%) en el brazo screening y 278 (14,9%) en el control, sin diferencias entre brazos en términos de mortalidad cáncer-específica (p = 0,907) ni por todas las causas (p = 0,399). Las principales causas de muerte encontradas fueron neoplasia (54,0%), cardiovascular (17,6%), respiratoria (8,7%) y digestiva (4,0%), sin diferencia entre brazos. De los 334 pacientes fallecidos por neoplasia tan solo 12 (3,6%) murieron por CaP. Conclusiones: El screening del CaP produce una migración del diagnóstico hacia estadios más precoces. No obstante, no hemos demostrado un beneficio en términos de supervivencia global ni cáncer-específica tras más de 15 años de seguimiento. La baja mortalidad por esta enfermedad en nuestro entorno podría ser uno de los principales factores para explicar estos resultados


Objective: The role of prostate cancer (PC) screening is currently being questioned. The objective of the European Randomized Study of Screening for Prostate Cancer (ERSPC) was to demonstrate whether PC screening reduced mortality from this disease. The results from the Spanish branch of this study are presented: all-cause and cancer-specific mortality, the characteristics of the detected tumors, primary treatments and progression to advanced disease. Material and methods: A total of 18,612 men, between the ages of 45 and 70, were invited to participate in the study, excluding those with a life expectancy of less than 10 years. The men were randomized to the screening arm (serum prostate-specific antigen [PSA] reading) or the control arm (no diagnostic tests). Randomized transrectal ultrasound-guided sextant prostate biopsies were indicated for the men in the screening arm with PSA levels ≥ 3 ng/ml. The detected PCs were identified (stage and primary treatment), as well as the deaths that occurred (date and cause of death). Results: The study was performed with 4276 men (2415 in the screening arm and 1861 in the control arm). The median age and serum PSA level were 57 years and 0.90 ng/mL, respectively. The median follow-up time was 15.8 years. A total of 242 PCs were diagnosed, 162 (6.7%) in the screening arm and 80 (4.3%) in the control arm (P < .001). Of these, 214 (88.4%) had an organ-confined clinical stage at onset (91.4% in the screening arm vs. 82.5% in the control arm; P = .024). A total of 112 patients (46.3%) underwent radical prostatectomy, 53 (21.9%) underwent prostate radiation therapy, 24 (9.9%) underwent hormone therapy and 47 (19.4%) were kept under observation. A total of 18 PCs progressed to advanced disease (M+ or PSA levels > 100 ng/mL), with no differences between the study arms (P = .938). A total of 618 (14.5%) patients died during follow-up: 340 (14.1%) in the screening arm and 278 (14.9%) in the control arm, with no differences between the arms in terms of cancer-specific (P = .907) or all-cause (P = .399) mortality. The main causes of death were neoplasia (54.0%), cardiovascular (17.6%), respiratory (8.7%) and gastrointestinal (4.0%), with no difference between study arms. Of the 334 patients who died from neoplasia, only 12 (3.6%) died from PC. Conclusions: PC screening results in a shifting of the diagnosis towards earlier stages. Nevertheless, we have not demonstrated a benefit in terms of overall or cancer-specific survival after more than 15 years of follow-up. The low mortality from this disease in our community could be one of the main factors that explain these results


Subject(s)
Adult , Aged , Humans , Male , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/therapy , Prostate-Specific Antigen/analysis , Early Detection of Cancer , Ultrasound, High-Intensity Focused, Transrectal , Diagnostic Techniques and Procedures , Neoplasm Staging , Treatment Outcome
16.
Actas Urol Esp ; 39(7): 405-13, 2015 Sep.
Article in English, Spanish | MEDLINE | ID: mdl-25777669

ABSTRACT

OBJECTIVE: The role of prostate cancer (PC) screening is currently being questioned. The objective of the European Randomized Study of Screening for Prostate Cancer (ERSPC) was to demonstrate whether PC screening reduced mortality from this disease. The results from the Spanish branch of this study are presented: all-cause and cancer-specific mortality, the characteristics of the detected tumors, primary treatments and progression to advanced disease. MATERIAL AND METHODS: A total of 18,612 men, between the ages of 45 and 70, were invited to participate in the study, excluding those with a life expectancy of less than 10 years. The men were randomized to the screening arm (serum prostate-specific antigen [PSA] reading) or the control arm (no diagnostic tests). Randomized transrectal ultrasound-guided sextant prostate biopsies were indicated for the men in the screening arm with PSA levels ≥3ng/ml. The detected PCs were identified (stage and primary treatment), as well as the deaths that occurred (date and cause of death). RESULTS: The study was performed with 4276 men (2415 in the screening arm and 1861 in the control arm). The median age and serum PSA level were 57 years and 0.90ng/mL, respectively. The median follow-up time was 15.8 years. A total of 242 PCs were diagnosed, 162 (6.7%) in the screening arm and 80 (4.3%) in the control arm (P<.001). Of these, 214 (88.4%) had an organ-confined clinical stage at onset (91.4% in the screening arm vs. 82.5% in the control arm; P=.024). A total of 112 patients (46.3%) underwent radical prostatectomy, 53 (21.9%) underwent prostate radiation therapy, 24 (9.9%) underwent hormone therapy and 47 (19.4%) were kept under observation. A total of 18 PCs progressed to advanced disease (M+ or PSA levels >100ng/mL), with no differences between the study arms (P=.938). A total of 618 (14.5%) patients died during follow-up: 340 (14.1%) in the screening arm and 278 (14.9%) in the control arm, with no differences between the arms in terms of cancer-specific (P=.907) or all-cause (P=.399) mortality. The main causes of death were neoplasia (54.0%), cardiovascular (17.6%), respiratory (8.7%) and gastrointestinal (4.0%), with no difference between study arms. Of the 334 patients who died from neoplasia, only 12 (3.6%) died from PC. CONCLUSIONS: PC screening results in a shifting of the diagnosis towards earlier stages. Nevertheless, we have not demonstrated a benefit in terms of overall or cancer-specific survival after more than 15 years of follow-up. The low mortality from this disease in our community could be one of the main factors that explain these results.


Subject(s)
Early Detection of Cancer , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/therapy , Aged , Humans , Male , Middle Aged , Treatment Outcome
17.
J Natl Cancer Inst ; 107(1): 366, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25505238

ABSTRACT

BACKGROUND: The results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial showed a statistically significant 29% prostate cancer mortality reduction for the men screened in the intervention arm and a 23% negative impact on the life-years gained because of quality of life. However, alternative prostate-specific antigen (PSA) screening strategies for the population may exist, optimizing the effects on mortality reduction, quality of life, overdiagnosis, and costs. METHODS: Based on data of the ERSPC trial, we predicted the numbers of prostate cancers diagnosed, prostate cancer deaths averted, life-years and quality-adjusted life-years (QALY) gained, and cost-effectiveness of 68 screening strategies starting at age 55 years, with a PSA threshold of 3, using microsimulation modeling. The screening strategies varied by age to stop screening and screening interval (one to 14 years or once in a lifetime screens), and therefore number of tests. RESULTS: Screening at short intervals of three years or less was more cost-effective than using longer intervals. Screening at ages 55 to 59 years with two-year intervals had an incremental cost-effectiveness ratio of $73000 per QALY gained and was considered optimal. With this strategy, lifetime prostate cancer mortality reduction was predicted as 13%, and 33% of the screen-detected cancers were overdiagnosed. When better quality of life for the post-treatment period could be achieved, an older age of 65 to 72 years for ending screening was obtained. CONCLUSION: Prostate cancer screening can be cost-effective when it is limited to two or three screens between ages 55 to 59 years. Screening above age 63 years is less cost-effective because of loss of QALYs because of overdiagnosis.


Subject(s)
Biomarkers, Tumor/blood , Early Detection of Cancer/economics , Early Detection of Cancer/methods , Mass Screening/economics , Mass Screening/methods , Prostate-Specific Antigen/blood , Prostatic Neoplasms/economics , Prostatic Neoplasms/mortality , Quality of Life , Quality-Adjusted Life Years , Age Factors , Aged , Computer Simulation , Cost-Benefit Analysis , Europe , False Positive Reactions , Humans , Male , Middle Aged , Prostatic Neoplasms/blood , Prostatic Neoplasms/diagnosis , Time Factors
18.
Acta neurol. colomb ; 30(2): 128-133, abr.-jun. 2014. ilus, tab
Article in Spanish | LILACS | ID: lil-724897

ABSTRACT

Las reacciones adversas cutáneas asociadas al uso de Lamotrigina, abarcan una gama amplia de presentaciones, desde las más leves, como es el caso del eritema multiforme mayor, hasta las más severas como la necrolisis epidérmica tóxica y el síndrome de Stevens Johnson. El presente artículo presenta un caso de un cuadro clínico clásico de reacción cutánea severa secundaria al uso de Lamotrigina, cuya evolución posterior fue favorable sin requerir manejo diferente al instaurado en casos de reacción leve. Se concluye que las manifestaciones clínicas se pueden enmascarar al realizar el diagnóstico basado solo en algunos hallazgos clínicos o evaluándolos de forma aislada, una perspectiva a considerar antes de prescribir este tipo de medicamento y su interacción con otros del mismo grupo farmacológico.


Cutaneous adverse reactions associated with the use of Lamotrigine contain a broad spectrum of presentations, from mild, as in the case of erythema multiforme major, to the most severe, such as toxic epidermal necrolysis and Stevens Johnson Syndrome. In this paper we present a classic case of severe skin reaction secondary to the use of lamotrigine, the latter evolution of which was favorable without requiring different management from that established for mild reactions. We conclude that the clinical manifestations may be masked when performing some diagnoses based only on clinical findings or evaluating them in isolation, a perspective to consider before prescribing this type of medication and interaction with others of the same pharmacological group.

19.
Prostate Cancer Prostatic Dis ; 17(2): 187-91, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24614694

ABSTRACT

BACKGROUND: To present the long-term results of a prostate cancer (PC) screening trial conducted in a Mediterranean setting. METHODS: A total of 4276 men aged 45-70 years were randomized to screening arm (PSA test performed) and control arm (no tests). Transrectal ultrasonography-guided sextant prostate biopsy was conducted when PSA > or = 3 ng ml(-1). Date and cause of death were retrieved from death certificates. PC incidence, and disease-specific and overall mortality curves were plotted and comparison between arms was made. Analysis of causes of death was also performed. RESULTS: Median age at randomization was 57.0 years. Median follow-up time was 15.2 years. A total of 241 men were diagnosed with PC, 161 (6.7%) in the screening arm and 80 (4.3%) in the control arm (P<0.01). Eventually, 554 men (13%) died. No difference in all-cause mortality was found between arms (P=0.34). Only 10 men (10/4276, 0.23%) died from PC, no differences between arms (P=0.67). Overall, the main causes of death were malignancy (54.2%), cardiovascular (17.9%) and respiratory (9.2%) diseases. Main cancer causes of death were lung and bronchus cancer (37.2%), colorectum (15.0%) and stomach (9.0%) cancer. PC only accounted for 3.0% of all malignant causes of death (ranked 10th). CONCLUSIONS: Our study failed to demonstrate benefits of PC screening in terms of all-cause and PC-specific mortality after a median follow-up of 15 years. The limited sample size and the low long-term PC mortality observed in our setting were probably the most important factors to explain these results.


Subject(s)
Prostatic Neoplasms/epidemiology , Prostatic Neoplasms/mortality , Aged , Biopsy/methods , Early Detection of Cancer/methods , Humans , Incidence , Kallikreins/metabolism , Male , Middle Aged , Prostate-Specific Antigen/metabolism , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/metabolism , Spain/epidemiology , Time Factors
20.
Radiología (Madr., Ed. impr.) ; 55(5): 398-407, sept. 2013.
Article in Spanish | IBECS | ID: ibc-115436

ABSTRACT

Objetivos. Evaluar qué porcentaje de hernias de disco desaparece tras un año de seguimiento y a qué ritmo; valorar si el uso del realce con gadolinio en RM tiene valor predictivo de la desaparición de la hernia; y estudiar si el patrón del realce ayuda a predecir la desaparición del fragmento. Material y métodos. Se incluyeron en este estudio prospectivo 118 pacientes con clínica de lumbociática aguda y que presentaban una hernia de disco diagnosticada mediante TC. A 72 pacientes se les realizó una RM con gadolinio cada 6 meses hasta el año o hasta que la hernia de disco desaparecía, y se relacionó la presencia de protrusión, extrusión y el patrón de realce con la desaparición o persistencia del material discal. Se realizó un estudio estadístico univariable y multivariable. Resultados. Un 59% de las hernias de disco desaparecieron tras un año de seguimiento, y de ellas el 66% lo hicieron en los primeros 8 meses. Un 83% de las hernias extruidas desaparecieron, y este dato tiene significación estadística en el análisis multivariable (p < 0,005). La ausencia de realce tiene asociación con la persistencia de la hernia, con significación estadística en el análisis univariable. El patrón de realce no ayuda a predecir la desaparición de la hernia. Hubo 5 hernias que desaparecieron muy pronto, dentro de los primeros 2 meses. Conclusiones. Un alto porcentaje de hernias de disco desaparecen, se ha encontrado la asociación estadísticamente significativa entre extrusión y desaparición, y falta de correlación entre el patrón de captación de gadolinio y la desaparición de la hernia(AU)


Objectives. To evaluate the percentage of disc hernias that have disappeared after one year of follow-up and the time to disappearance. To determine whether gadolinium enhancement is useful for predicting whether the hernia will disappear. To analyze whether the pattern of enhancement can help predict whether the fragment will disappear. Material and methods. This prospective study included 118 patients with acute symptoms of lumbosciatica and a herniated disc diagnosed by CT. In 72 patients, we performed gadolinium-enhanced MRI every 6 months for one year or until the herniation disappeared; we related the findings of protrusion, extrusion, and the enhancement pattern with the disappearance or persistence of herniated disc material. We analyzed the results with univariate and multivariate statistics. Results. The 59% of the hernias disappeared within 1 year of follow-up and 66% disappeared within the first 8 months of follow-up. The 83% of the extruded hernias disappeared, and this was significant in the multivariate analysis (P<.005). The absence of enhancement was significantly associated with the persistence of the hernia in the univariate analysis. The enhancement pattern was not useful for predicting whether the hernia would disappear. Five hernias disappeared within the first two months. Conclusions. A high percentage of disc hernias disappear. We found a significant association between extrusion and disappearance but no correlation between the pattern of gadolinium uptake and the disappearance of the herni(AU)


Subject(s)
Humans , Male , Female , Natural History of Diseases , Hernia , Gadolinium , Gadolinium/radiation effects , Prognosis , Magnetic Resonance Imaging/instrumentation , Magnetic Resonance Imaging/methods , Magnetic Resonance Spectroscopy , Lumbosacral Region/pathology , Lumbosacral Region , Prospective Studies , Multivariate Analysis , Odds Ratio , Confidence Intervals , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...